Clay Siegall is the brain behind Seattle Genetics, a company whose primary objective is to develop cancer remedies. As of the moment, Clay is the incumbent president and CEO of the firm. Using his in-depth scientific knowledge, Clay has transformed Seattle Genetics into a leading oncology research institution as well as supporting philanthropic causes. Under his stewardship, the company has broken new grounds in developing antibody-drug conjugates, including ADCETRIS, an internationally acclaimed drug.
Moreover, Clay has overseen several mergers with an array of leading pharmaceutical enterprises. Among the leading corporations that Seattle Genetics has teamed up with are GlaxoSmithKline and Roche. These transactions have proven to be lucrative to Seattle Genetics, netting the firm an enormous $350 million worth of revenue. Besides, Clay has demonstrated his unparalleled entrepreneurial nous by masterminding record-breaking fundraisers, including an extremely prosperous IPO in 2001.
Clay Siegall boasts of an impressive career recording, having served in different capacities in multiple prominent institutions. Before inaugurating Seattle Genetics, he worked for a substantial period under Bristol-Myers Squibb. Other notable firms in Siegall’s work portfolio include National Cancer Institute and National Institute of Health. Furthermore, Claus sits on various boards, such as the Washington Roundtable.
In his illustrious career, numerous prestigious accolades have been bestowed on Clay. Some of the outstanding awards include the Entrepreneur of the Year, bequeathed by Ernst &Young, and Alumnus of the Year, conferred by the University of Maryland.
The idea of Seattle Genetics was incepted with the aim of mitigating the effects of cancer on patients. At a tender age, Clay experienced the tribulations of cancer patients, as his father was a victim of the condition. At that time, the resources allocated towards combatting the cancer menace were not only scanty but also incompetent. This spurred him to pursue further education on oncology, a dream that was realized after he received a doctorate from the George Washington University.
Since graduating, Clay has maintained his dedication towards finding a lasting solution to this disease. His advice to young entrepreneurs is to interact with established business persons, as they best source for learning new developmental strategies.
Also, Clay Siegall ascribes his unprecedented prosperity to teaming up with like-minded parties. He disclosed that through partnerships, his firm had embraced new techniques, which have resulted in better customer treatment.